Major Depressive Disorder trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Major Depressive Disorder. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month5 studies across 4 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6 | Phase 3 | Recruiting | Aug 2026 | ≤ 11 d | 2026-08-03 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ANRO | Alto Neuroscience | Study of ALTO-300 in MDDNCT05922878To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS). | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2025-07-24 |
| SUPN | Supernus Pharmaceuticals, Inc. | Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-03-24 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24 | Phase 4 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-16 |
| XENE | Xenon Pharmaceuticals Inc. | An Open-Label Study of Azetukalner in Major Depressive DisorderNCT06922110Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest | Phase 3 | Enrolling by invitation | Jan 2027 | ≤ 164 d | 2026-08-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Major Depressive Disorder
most recently updated first251 studies match. Showing the first 100 of 251 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score | Phase 2 | Not yet recruiting | Drug: BMS-986511, Placebo | Major Depressive Disorder | 200 | 2026-10-30 | 2028-11-06 | in 809 d | 2026-08-19 |
| SPTX | Seaport Therapeutics | $1.3B | A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240Change From Baseline to Day 42 in Hamilton Depression Rating Scale-17 (HAM-D-17) Total Score | Phase 2 | Recruiting | Drug: SPT-300, Placebo | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | 360 | 2025-06-19 | Mar 2027 | ≤ 223 d | 2026-08-17 |
| SPTX | Seaport Therapeutics | $1.3B | An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700Safety and tolerability assessments based on Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and validated clinical scales and procedures | Phase 2 | Enrolling by invitation | Drug: SPT-300 | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | 360 | 2025-09-02 | May 2027 | ≤ 284 d | 2026-08-17 |
| RLMD | Relmada Therapeutics, Inc. | $517M | Individual Patient Esmethadone (REL-1017) Expanded Access ProgramNCT06009003expanded access | — | No longer available | Drug: REL-1017 | Major Depressive Disorder, Depression | — | — | — | — | 2026-08-12 |
| NBIX | Neurocrine Biosciences | $15.7B | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06911112Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56 | Phase 3 | Recruiting | Drug: NBI-1065845, Placebo | Major Depressive Disorder | 200 | 2025-03-31 | Jul 2027 | ≤ 345 d | 2026-08-11 |
| CMPS | COMPASS Pathways | $1.9B | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268COMP360 25 mg versus placebo for the change from baseline in MADRS total score | Phase 3 | Completed | Drug: Psilocybin | Treatment Resistant Depression | 258 | 2023-01-24 | 2025-05-28actual | — | 2026-08-10 |
| CMPS | COMPASS Pathways | $1.9B | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. | Phase 3 | Active, not recruiting | Drug: Psilocybin | Treatment Resistant Depression | 572 | 2023-02-14 | 2025-11-13actual | — | 2026-08-10 |
| NBIX | Neurocrine Biosciences | $15.7B | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06963021Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56 | Phase 3 | Recruiting | Drug: NBI-1065845, Placebo | Major Depressive Disorder | 200 | 2025-05-30 | Jul 2027 | ≤ 345 d | 2026-08-10 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 | Phase 2 | Recruiting | Drug: ACP-211, Placebo | Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | 153 | 2025-11-14 | Aug 2027 | ≤ 376 d | 2026-08-06 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6 | Phase 3 | Recruiting | Drug: Azetukalner, Placebo | Major Depressive Disorder | 450 | 2024-12-20 | Aug 2026 | ≤ 11 d | 2026-08-03 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | An Open-Label Study of Azetukalner in Major Depressive DisorderNCT06922110Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest | Phase 3 | Enrolling by invitation | Drug: Azetukalner | Major Depressive Disorder | 460 | 2025-03-18 | Jan 2027 | ≤ 164 d | 2026-08-03 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)NCT07076407Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6 | Phase 3 | Recruiting | Drug: Azetukalner, Placebo | Major Depressive Disorder | 450 | 2025-07-08 | May 2027 | ≤ 284 d | 2026-08-03 |
| NBIX | Neurocrine Biosciences | $15.7B | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Phase 3 | Recruiting | Drug: NBI-1065845 | Major Depressive Disorder | 850 | 2025-04-16 | May 2029 | ≤ 1,015 d | 2026-07-24 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT07196501Time from Randomization to Relapse | Phase 3 | Recruiting | Drug: NBI-1065845, Placebo | Major Depressive Disorder | 550 | 2025-08-18 | Jul 2028 | ≤ 711 d | 2026-07-24 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderNCT06267846Change in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5 | Phase 2 | Completed | Drug: NBI-1070770, Placebo | Major Depressive Disorder | 73 | 2024-03-20 | 2025-07-25actual | — | 2026-07-17 |
| NMRA | Neumora Therapeutics, Inc. | $286M | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score | Phase 3 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 430 | 2023-12-20 | 2026-05-06actual | — | 2026-07-06 |
| NMRA | Neumora Therapeutics, Inc. | $286M | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score | Phase 3 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 422 | 2023-12-21 | 2026-05-04actual | — | 2026-07-06 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24 | Phase 4 | Recruiting | Drug: Valbenazine | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 50 | 2025-08-29 | Jan 2027 | ≤ 164 d | 2026-06-16 |
| LIVN | LivaNova | $4.4B | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant DepressionNCT03887715Montgomery Åsberg Depression Rating Scale (MADRS) Rate of Response | Not applicable | Recruiting | Device: Vagus Nerve Stimulation (VNS) | Treatment Resistant Depression | 6,800 | 2019-09-26 | 2028-02-28 | in 557 d | 2026-06-15 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderNCT07276997Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. | Phase 2 | Recruiting | Drug: Icalcaprant, Placebo for Icalcaprant | Major Depressive Disorder | 195 | 2025-12-18 | Sep 2027 | ≤ 406 d | 2026-06-15 |
| NMRA | Neumora Therapeutics, Inc. | $286M | Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales | Phase 3 | Active, not recruiting | Drug: NMRA-335140 | Major Depressive Disorder | 1,000 | 2023-11-10 | Jun 2027 | ≤ 314 d | 2026-06-09 |
| TNXP | Tonix Pharmaceuticals, Inc. | $217M | A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)NCT07621237Change from Baseline (Visit 2) in the MADRS total score at Week 6. | Phase 2 | Recruiting | Drug: TNX-102 SL, Placebo sublingual tablet | Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression | 360 | Jun 2026 | Feb 2028 | ≤ 558 d | 2026-06-02 |
| ANRO | Alto Neuroscience | $1.3B | PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593Single Dose Period: To evaluate pharmacodynamic measures in patients with MDD after single doses of 25 μg ALTO-203, 75 μg ALTO-203, and placebo as measured by the alertness and mood components of the Bond-Lader Visual Analog Scale (BL-VAS). | Phase 2 | Completed | Drug: ALTO-203 25 μg, ALTO-203 75 μg, Placebo | Major Depressive Disorder, Anhedonia | 69 | 2024-03-25 | 2025-04-14actual | — | 2026-04-17 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. | Phase 2 | Recruiting | Drug: SPN-821 2400 mg, Placebo | Major Depressive Disorder (MDD) | 230 | 2026-01-19 | 2026-12-31 | in 133 d | 2026-03-24 |
| BWAY | Brainsway | — | New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)NCT06357832Change in Hamilton Depression Rating Scale (HDRS)-21 score in the investigational group | Not applicable | Completed | Device: Brainsway Deep TMS System | Major Depressive Disorder | 104 | 2024-04-29 | 2025-02-26actual | — | 2026-03-10 |
| VNDA | Vanda Pharmaceuticals | $329M | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) | Phase 3 | Recruiting | Drug: Milsaperidone, Placebo | Major Depressive Disorder (MDD) | 500 | 2025-03-03 | Mar 2028 | ≤ 589 d | 2026-02-27 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)NCT04634669results2026-01-28Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05 | Phase 2 | Terminatedsponsor's stated reason: This study was terminated once overall program objectives were met. | Drug: AXS-05 (dextromethorphan-bupropion) | Treatment Resistant Depression, Major Depressive Disorder | 181 | 2020-09-23 | 2022-02-18actual | — | 2026-01-28 |
| LIVN | LivaNova | $4.4B | A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.NCT03320304observationalThe primary endpoint of this study is response defined as reduction in Montgomery Åsberg Depression Rating Scale (MADRS) total score of at least 50% from baseline to 12 months post implant. | — | Recruiting | Device: Vagal Nerve Simulation (VNS) Therapy | Treatment Resistant Depression | 500 | 2017-12-14 | 2029-12-01 | in 1,199 d | 2026-01-26 |
| NBIX | Neurocrine Biosciences | $15.7B | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaNCT05859698results2026-01-16Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24 | Phase 4 | Completed | Drug: Valbenazine | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 59 | 2023-05-09 | 2024-12-27actual | — | 2026-01-16 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419Montgomery-Åsberg Depression Rating Scale (MADRS) | Phase 3 | Completed | Drug: Solriamfetol 300 mg, Placebo | Major Depressive Disorder | 346 | 2024-03-18 | 2024-12-31actual | — | 2026-01-05 |
| NMRA | Neumora Therapeutics, Inc. | $286M | Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426Change from Baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score | Phase 3 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 383 | 2023-09-20 | 2024-12-03actual | — | 2025-11-26 |
| NBIX | Neurocrine Biosciences | $15.7B | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06786624Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56 | Phase 3 | Recruiting | Drug: NBI-1065845, Placebo | Major Depressive Disorder | 200 | 2025-01-22 | Jul 2027 | ≤ 345 d | 2025-10-29 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive DisorderNCT06618118Number of Participants Experiencing Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: Fosigotifator, Placebo | Major Depressive Disorder (MDD) | 20 | 2024-10-23 | 2025-09-23actual | — | 2025-09-30 |
| ANRO | Alto Neuroscience | $1.3B | Phase 2b Study of ALTO-100 in MDDNCT05712187To assess efficacy of ALTO-100 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. | Phase 2 | Completed | Drug: ALTO-100, Placebo | Major Depressive Disorder | 301 | 2023-01-10 | 2024-09-05actual | — | 2025-09-08 |
| CMPS | COMPASS Pathways | $1.9B | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546Safety and tolerability of COMP360 Psilocybin | Phase 2 | Active, not recruiting | Drug: Psilocybin | Major Depressive Disorder | 102 | 2023-01-30 | Sep 2025 | — | 2025-08-19 |
| ANRO | Alto Neuroscience | $1.3B | Study of ALTO-300 in MDDNCT05922878To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS). | Phase 2 | Recruiting | Drug: ALTO-300, Placebo | Major Depressive Disorder | 321 | 2023-06-08 | Dec 2026 | ≤ 133 d | 2025-07-24 |
| NMRA | Neumora Therapeutics, Inc. | $286M | Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230results2025-05-29Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 | Phase 2 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 204 | 2020-01-03 | 2022-04-08actual | — | 2025-05-29 |
| BIIB | Biogen | $31.4B | Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)NCT05655507Plasma Concentrations of Zuranolone | Phase 1 | Completed | Drug: Zuranolone | Major Depressive Disorder | 19 | 2023-04-19 | 2024-10-18actual | — | 2025-03-26 |
| RLMD | Relmada Therapeutics, Inc. | $517M | Safety of REL-1017 for Major Depressive DisorderNCT04855760results2024-08-09Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: REL-1017 | Major Depressive Disorder | 627 | 2021-04-01 | 2023-07-27actual | — | 2025-02-11 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsNCT06223880Time from randomization to relapse of depressive symptoms | Phase 4 | Recruiting | Drug: AXS-05, Bupropion | Major Depressive Disorder | 350 | 2023-12-27 | Mar 2026 | — | 2025-01-23 |
| NBIX | Neurocrine Biosciences | $15.7B | Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)NCT05203341Change from Baseline in Total Montgomery Åsberg Depression Rating Scale (MADRS) Score at Day 28 | Phase 2 | Completed | Drug: Placebo, NBI-1065845 | Major Depressive Disorder | 183 | 2022-02-21 | 2024-01-10actual | — | 2025-01-15 |
| LLY | Eli Lilly and Company | $1.15T | Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical TrialNCT00071708expanded access | — | Approved for marketing | Drug: Duloxetine Hydrochloride | Major Depressive Disorder, Fibromyalgia, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder | — | — | — | — | 2025-01-10 |
| LIVN | LivaNova | $4.4B | The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive EpisodesNCT04753385observationalPercentage of PHQ-8 tasks | — | Terminatedsponsor's stated reason: UNCOVER terminated early based on low enrollment and lack of device data collected making analysis unfeasible. | — | Treatment Resistant Depression | 138 | 2021-03-23 | 2024-09-06actual | — | 2024-12-20 |
| 4503.T | Astellas Pharma Inc | $26.0B | Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive DisorderNCT01725282results2014-08-28Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Phase 2 | Completed | Drug: quetiapine extended release (XR), Placebo | Major Depressive Disorder | 172 | 2011-12-14 | 2013-08-24actual | — | 2024-11-15 |
| 4503.T | Astellas Pharma Inc | $26.0B | Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive DisorderNCT01919008Maximum plasma concentration (Cmax) of unchanged quetiapine | Phase 1 | Completed | Drug: FK949E | Major Depressive Disorder | 16 | 2012-03-26 | 2012-06-22actual | — | 2024-10-31 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderNCT05376150Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. | Phase 2 | Completed | Drug: XEN1101 10 mg, XEN1101 20 mg, Placebo | Major Depressive Disorder | 168 | 2022-05-19 | 2023-09-18actual | — | 2024-09-19 |
| BIIB | Biogen | $31.4B | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)NCT03864614results2024-07-18Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: SAGE-217 | Major Depressive Disorder | 1,515 | 2019-02-27 | 2023-06-22actual | — | 2024-08-27 |
| RLMD | Relmada Therapeutics, Inc. | $517M | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04688164results2024-03-26Change in the MADRS10 Total Score From Baseline to Day 28 | Phase 3 | Completed | Drug: REL-1017, Placebo | Major Depressive Disorder | 227 | 2021-01-08 | 2022-11-01actual | — | 2024-08-27 |
| NBIX | Neurocrine Biosciences | $15.7B | Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDDNCT05165394results2024-07-31Change in Anhedonia Severity, as Measured by Change in DARS Score From Baseline to Day 57 | Phase 2 | Completed | Drug: Placebo, NBI-1065846 | Anhedonia, Major Depressive Disorder | 93 | 2021-11-30 | 2023-07-07actual | — | 2024-07-31 |
| ANRO | Alto Neuroscience | $1.3B | ALTO-300 in DepressionNCT05118750To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Montgomery-Åsberg Depression Rating Scale (MADRS) | Phase 2 | Completed | Drug: ALTO-300 oral (PO) tablet | Major Depressive Disorder | 91 | 2021-12-13 | 2023-05-05actual | — | 2024-04-30 |
| ANRO | Alto Neuroscience | $1.3B | ALTO-300 in Depression (ALTO-300-004)NCT05157945To understand the relationship between baseline biology and change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-300 | Phase 2 | Completed | Drug: ALTO-300 PO Tablet | Major Depressive Disorder | 148 | 2022-02-03 | 2023-04-26actual | — | 2024-04-26 |
| RLMD | Relmada Therapeutics, Inc. | $517M | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)NCT05081167results2024-03-26Change in the MADRS10 Total Score From Baseline to Day 28 | Phase 3 | Completed | Drug: REL-1017, Placebo | Major Depressive Disorder | 232 | 2021-06-02 | 2022-09-13actual | — | 2024-03-26 |
| ANRO | Alto Neuroscience | $1.3B | Pilot Decentralized TrialNCT05419869To understand the relationship between baseline biology and score change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-100 from start of dosing to end of treatment | Phase 2 | Completed | Drug: ALTO-100 PO Tablet | Major Depressive Disorder | 21 | 2022-06-01 | 2023-01-13actual | — | 2024-01-18 |
| ANRO | Alto Neuroscience | $1.3B | ALTO-100 in MDD and/or PTSDNCT05117632To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Montgomery-Åsberg Depression Rating Scale (MADRS) | Phase 2 | Completed | Drug: ALTO-100 PO tablet | Major Depressive Disorder, Post Traumatic Stress Disorder | 245 | 2021-12-20 | 2022-12-01actual | — | 2023-12-01 |
| BIIB | Biogen | $31.4B | A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderNCT03672175results2022-11-10Change From Baseline in the 17-item HAM-D Total Score at Day 15 | Phase 3 | Completed | Drug: SAGE-217, Placebo | Major Depressive Disorder | 581 | 2018-11-19 | 2019-09-24actual | — | 2023-11-29 |
| BIIB | Biogen | $31.4B | A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaNCT03771664results2022-10-20Average Change From Baseline in Sleep Efficiency (SE) as Assessed by Polysomnogram (PSG) at Days 13 and 14 | Phase 3 | Terminatedsponsor's stated reason: internal company decision | Drug: SAGE-217, Placebo | Major Depressive Disorder, Insomnia | 87 | 2019-02-04 | 2019-12-20actual | — | 2023-11-29 |
| BIIB | Biogen | $31.4B | A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderNCT04007367results2022-10-03Time to Relapse During the DB Phase | Phase 3 | Terminatedsponsor's stated reason: Internal company decision | Drug: SAGE-217, Placebo | Major Depressive Disorder | 53 | 2019-08-06 | 2020-01-06actual | — | 2023-11-29 |
| CMPS | COMPASS Pathways | $1.9B | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionNCT04739865results2023-11-09Improvement in Depressive Symptoms | Phase 2 | Completed | Drug: Psilocybin | Treatment Resistant Depression | 19 | 2020-08-10 | 2021-10-14actual | — | 2023-11-09 |
| CMPS | COMPASS Pathways | $1.9B | The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200results2023-04-24Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3 | Phase 2 | Completed | Drug: Psilocybin | Treatment Resistant Depression | 233 | 2019-03-01 | 2021-07-30actual | — | 2023-04-24 |
| ABBV | AbbVie | $457.5B | Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03738215results2022-10-25Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) | Phase 3 | Completed | Drug: Cariprazine, Placebo | Major Depressive Disorder | 759 | 2018-11-09 | 2021-09-30actual | — | 2022-10-25 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Trial of AXS-05 in Patients With Major Depressive DisorderNCT04019704results2022-10-12Change in MADRS Total Score From Baseline to Week 6 | Phase 3 | Completed | Drug: AXS-05, Placebo | Depression, Major Depressive Disorder | 327 | 2019-06-20 | 2019-11-26actual | — | 2022-10-12 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Open-Label Safety Study of AXS-05 in Subjects With DepressionNCT04039022results2022-10-12Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05 | Phase 3 | Completed | Drug: AXS-05 (dextromethorphan and bupropion) oral tablets | Major Depressive Disorder, Treatment Resistant Depression, Depression | 876 | 2019-07-08 | 2020-10-23actual | — | 2022-10-12 |
| CMPS | COMPASS Pathways | $1.9B | Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)NCT04519957observationalLong-term efficacy of psilocybin | — | Completed | — | Treatment Resistant Depression | 66 | 2020-07-20 | 2022-08-11actual | — | 2022-09-22 |
| ABBV | AbbVie | $457.5B | The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03739203results2022-09-21Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score | Phase 3 | Completed | Drug: Cariprazine, Placebo, Antidepressant Therapy (ADT) | Major Depressive Disorder | 752 | 2018-11-10 | 2021-09-06actual | — | 2022-09-21 |
| PRAX | Praxis Precision Medicines | $10.3B | A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderNCT04969510Change from baseline in HAM-D17 total score at Day 15 | Phase 2 | Completed | Drug: 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo | Major Depressive Disorder | 110 | 2021-06-24 | 2022-07-15actual | — | 2022-08-19 |
| HLUN-B.CO | H. Lundbeck A/S | — | Vortioxetine in Patients With Depression and Early DementiaNCT04294654Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score | Phase 4 | Completed | Drug: Vortioxetine | Major Depressive Disorder, Dementia | 82 | 2020-02-28 | 2022-07-06actual | — | 2022-08-08 |
| PRAX | Praxis Precision Medicines | $10.3B | A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15 | Phase 2/3 | Completed | Drug: PRAX-114, Placebo | Major Depressive Disorder | 216 | 2021-03-30 | 2022-05-05actual | — | 2022-07-21 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Mechanistic Evaluation of Response in TRD (MERIT)NCT04608396Relapse | Phase 2 | Completed | Drug: AXS-05, Placebo | Treatment Resistant Depression, Major Depressive Disorder | 44 | 2020-08-13 | 2021-07-30actual | — | 2022-07-12 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT04000009results2022-04-05Treatment-emergent Adverse Events (TEAEs) | Phase 3 | Terminatedsponsor's stated reason: The study was terminated for business reasons and not due to safety concerns. | Drug: Pimavanserin | Adjunctive Treatment of Major Depressive Disorder | 235 | 2019-06-06 | 2021-02-22actual | — | 2022-04-05 |
| HLUN-B.CO | H. Lundbeck A/S | — | Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in IndiaNCT04288895Number of participants with Treatment-Emergent Adverse Events | Phase 4 | Completed | Drug: Vortioxetine | Major Depressive Disorder | 400 | 2020-02-20 | 2022-02-11actual | — | 2022-03-18 |
| HLUN-B.CO | H. Lundbeck A/S | — | Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From DepressionNCT04448431Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score | Phase 4 | Completed | Drug: Vortioxetine, Desvenlafaxine | Major Depressive Disorder | 605 | 2020-06-18 | 2022-01-06actual | — | 2022-02-14 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT03968159results2021-11-17Change From Baseline to Week 5 in Hamilton Depression Scale (17 Items) (HAMD-17) Total Score | Phase 3 | Completed | Drug: Pimavanserin, Placebo | Adjunctive Treatment of Major Depressive Disorder | 298 | 2019-04-25 | 2020-04-30actual | — | 2021-11-17 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Assessing Symptomatic Clinical Episodes in DepressionNCT03595579results2021-09-24MADRS Score - Overall Change From Baseline | Phase 2 | Completed | Drug: AXS-05, Bupropion | Major Depressive Disorder | 97 | 2018-05-30 | 2019-01-07actual | — | 2021-09-24 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Effexor XR in Chinese Subjects With Major Depressive DisorderNCT00878748time from entering maintenance phase to recurrence of major depression | Phase 4 | Withdrawn | Drug: Effexor XR · Other: Effexor XR discontinue | Major Depressive Disorder | 0 | Apr 2009 | Oct 2011 | — | 2021-08-20 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent PatientsNCT04971291Montgomery-Åsberg Depression Rating Scale (MADRS) total score | Phase 2 | Unknown status | Drug: AXS-05, Bupropion SR | Major Depressive Disorder, Treatment Resistant Depression | 312 | 2021-04-14 | Jul 2021 | — | 2021-07-26 |
| HLUN-B.CO | H. Lundbeck A/S | — | Real-life Effectiveness of Vortioxetine in DepressionNCT03555136observationalSheehan Disability Scale (SDS) | — | Completed | Drug: Vortioxetine | Major Depressive Disorder | 992 | 2017-11-17 | 2021-01-31actual | — | 2021-05-27 |
| PFE | Pfizer | $155.3B | A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major DepressionNCT01098240results2013-06-26Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score at Week 14 | Phase 2 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Drug: CP-601,927 · Other: Placebo | Major Depressive Disorder | 297 | 2010-06-14 | 2011-09-12actual | — | 2021-05-03 |
| HLUN-B.CO | H. Lundbeck A/S | — | Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)NCT04220996Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score | Phase 4 | Completed | Drug: Vortioxetine | MDD, Anxiety Disorders | 100 | 2019-12-27 | 2021-03-09actual | — | 2021-04-20 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)NCT03188185results2021-03-15Change From Baseline to the End of Treatment (EOT) in the Montgomery Asberg Depression Rating Scale-10 (MADRS-10) Scores | Phase 3 | Completed | Drug: ALKS 5461, ALKS 5461 Placebo | Major Depressive Disorder | 278 | 2017-06-12 | 2020-02-26actual | — | 2021-04-08 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderNCT02741791Montgomery-Åsberg Depression Rating Scale (MADRS) total score | Phase 3 | Completed | Drug: AXS-05, Bupropion | Treatment Resistant Major Depressive Disorder | 312 | Mar 2016 | 2020-03-20actual | — | 2021-03-24 |
| PFE | Pfizer | $155.3B | Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQNCT02548949results2021-02-09observationalNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | — | Completed | — | Major Depressive Disorder | 700 | 2016-04-25 | 2020-02-12actual | — | 2021-02-09 |
| NVS | Novartis | — | Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411099To evaluate the change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17) | Phase 3 | Completed | Drug: agomelatine, placebo | Major Depressive Disorder | 508 | Dec 2006 | Jan 2008actual | — | 2020-12-23 |
| NVS | Novartis | — | Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411242Change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17) | Phase 3 | Completed | Drug: agomelatine, placebo | Major Depressive Disorder (MDD) | 503 | Dec 2006 | Jan 2008actual | — | 2020-12-23 |
| NVS | Novartis | — | A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)NCT00463242Change from Baseline to Week 8 on the total score Hamilton Depression Rating Scale | Phase 3 | Completed | Drug: Agomelatine, paroxetine, placebo | Major Depressive Disorder | 501 | Mar 2007 | Jun 2008actual | — | 2020-12-23 |
| NVS | Novartis | — | Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive DisorderNCT00467402Time to relapse, where relapse is defined by the occurrence of any one of the following: | Phase 3 | Completed | Drug: agomelatine, placebo | Major Depressive Disorder | 644 | Apr 2007 | Sep 2009actual | — | 2020-12-23 |
| BWAY | Brainsway | — | Brainsway DTMS for Treatment of MDD Using iTBSNCT04679753The primary outcome measure was the change from baseline in HDRS-21 scores at the 5 week visit. | Phase 4 | Completed | Device: Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS), Brainsway DTMS with High Frequency (HF) Stimulation | Major Depressive Disorder | 177 | 2019-01-01 | 2020-07-01actual | — | 2020-12-23 |
| NERV | Minerva Neurosciences | $217M | A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive DisorderNCT03446846results2020-12-17Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Phase 2 | Completed | Drug: MIN-117 5.0 mg, MIN-117 2.5 mg, Placebo | Major Depressive Disorder | 360 | 2018-03-30 | 2019-11-21actual | — | 2020-12-17 |
| ANRO | Alto Neuroscience | $1.3B | Leveraging EEG for Antidepressant Prediction With Duloxetine and BupropionNCT04388189Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score | Phase 4 | Withdrawnsponsor's stated reason: No participants enrolled | Drug: Duloxetine, Bupropion | Major Depressive Disorder | 0 | 2020-10-15 | 2023-05-30 | — | 2020-10-19 |
| ANRO | Alto Neuroscience | $1.3B | Leveraging EEG for Antidepressant Prediction With Sertraline and EscitalopramNCT04388202Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score | Phase 4 | Withdrawnsponsor's stated reason: No participants enrolled | Drug: Sertraline, Escitalopram | Major Depressive Disorder | 0 | 2020-10-15 | 2023-05-30 | — | 2020-10-19 |
| BWAY | Brainsway | — | Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression DisorderNCT00927173HDRS-21 | Not applicable | Completed | Device: Brainsway H-Coil Deep TMS System, Brainsway H-Coil Deep TMS System (Sham treatment) | Major Depressive Disorder | 233 | Sep 2009 | Mar 2012actual | — | 2020-07-15 |
| BWAY | Brainsway | — | Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)NCT03012724HDRS-21 Score Change From Baseline | Not applicable | Unknown status | Device: H7-Coil, H1-Coil | Major Depressive Disorder (MDD) | 106 | 2017-03-30 | Dec 2020 | — | 2020-07-15 |
| HLUN-B.CO | H. Lundbeck A/S | — | Study With Vortioxetine on Emotional Functioning in Patients With DepressionNCT03835715Change from baseline to Week 8 in Oxford Depression Questionnaire (ODQ) total score | Phase 4 | Completed | Drug: Vortioxetine | Major Depressive Disorder | 150 | 2019-02-05 | 2020-02-21actual | — | 2020-03-24 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)NCT03018340results2019-11-14Change From Baseline to Week 5 in the HAMD-17 Total Score | Phase 2 | Completed | Drug: Pimavanserin · Other: Placebo | Adjunctive Treatment of Major Depressive Disorder | 207 | Dec 2016 | Sep 2018actual | — | 2019-11-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Olanzapine and Fluoxetine for Treatment-resistant DepressionNCT01687478results2017-08-24Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS) | Phase 3 | Terminatedsponsor's stated reason: Interim assessment: Lack of efficacy | Drug: Olanzapine, Fluoxetine, Placebo | Treatment Resistant Depression | 176 | Sep 2012 | Nov 2015actual | — | 2019-10-09 |
| VTGN | VistaGen Therapeutics, Inc. | $11M | AV-101 as Adjunct Antidepressant Therapy in Patients With Major DepressionNCT03078322Montgomery Åsberg Depression Rating Scale 10-item version (MADRS-10) | Phase 2 | Completed | Drug: AV-101, Placebo | Major Depressive Disorder | 180 | 2018-03-05 | 2019-10-01actual | — | 2019-10-09 |
| HLUN-B.CO | H. Lundbeck A/S | — | Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With DepressionNCT03766867Change from baseline (Day 0) to Day 1 (24 h post-infusion) in MADRS-6 subscale score | Phase 2 | Completed | Drug: Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day, Placebo infusion, Placebo tablets | Major Depressive Disorder | 80 | 2018-12-03 | 2019-07-31actual | — | 2019-08-29 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)NCT02085135results2019-03-27Number of Subjects With Adverse Events (AEs) | Phase 3 | Completed | Drug: ALKS 5461 | Major Depressive Disorder | 66 | Feb 2014 | Sep 2014actual | — | 2019-08-14 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 StudyNCT02158533results2019-03-27Change From Baseline to Week 5 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score | Phase 3 | Completed | Drug: High Dose ALKS 5461, Low Dose ALKS 5461, Placebo | Major Depressive Disorder | 385 | May 2014 | Dec 2015actual | — | 2019-08-14 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 StudyNCT02218008results2019-03-27Change in Montgomery Asberg Depression Rating Scale (MADRS)-6 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for Stage 1, Week 6 for Stage 2) | Phase 3 | Completed | Drug: ALKS 5461, Placebo | Major Depressive Disorder | 407 | Jul 2014 | Sep 2016actual | — | 2019-08-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY2216684 and Theophylline in Healthy SubjectsNCT01263106results2019-07-08Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Theophylline | Phase 1 | Completed | Drug: LY2216684, Theophylline | Major Depressive Disorder | 21 | Dec 2010 | Jan 2011actual | — | 2019-07-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Major Depressive Disorder is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Major Depressive Disorder
- Treatment Resistant Depression
- Major Depressive Disorder (MDD)
- Major Depressive Disorders
- Adjunctive Treatment of Major Depressive Disorder
- MDD
- Major Depressive Disorder Patients
- Major Depressive Disorder With Anxious Distress
- Treatment Resistant Major Depressive Disorder
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Major Depressive Disorder” (a text search, wider than this page)